Kayne Anderson Rudnick Investment Management LLC Has $53.71 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Kayne Anderson Rudnick Investment Management LLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 129,902 shares of the company’s stock after selling 6,695 shares during the period. Kayne Anderson Rudnick Investment Management LLC’s holdings in IDEXX Laboratories were worth $53,707,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. MetLife Investment Management LLC increased its holdings in IDEXX Laboratories by 0.3% during the 4th quarter. MetLife Investment Management LLC now owns 25,245 shares of the company’s stock worth $10,437,000 after purchasing an additional 85 shares in the last quarter. Norinchukin Bank The raised its position in IDEXX Laboratories by 9.0% in the 4th quarter. Norinchukin Bank The now owns 5,594 shares of the company’s stock valued at $2,313,000 after buying an additional 460 shares during the last quarter. Ossiam lifted its stake in IDEXX Laboratories by 28.2% during the 4th quarter. Ossiam now owns 5,028 shares of the company’s stock valued at $2,079,000 after acquiring an additional 1,105 shares in the last quarter. Beck Mack & Oliver LLC boosted its holdings in IDEXX Laboratories by 3.8% during the 4th quarter. Beck Mack & Oliver LLC now owns 2,092 shares of the company’s stock worth $865,000 after acquiring an additional 77 shares during the last quarter. Finally, Capital Research Global Investors grew its stake in shares of IDEXX Laboratories by 44.4% in the 4th quarter. Capital Research Global Investors now owns 615,996 shares of the company’s stock worth $254,677,000 after acquiring an additional 189,436 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is owned by insiders.

Analyst Ratings Changes

IDXX has been the topic of a number of recent analyst reports. Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Finally, Barclays upped their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $523.75.

IDEXX Laboratories Price Performance

IDXX opened at $411.72 on Monday. The firm has a 50-day moving average price of $422.37 and a 200-day moving average price of $430.47. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $33.37 billion, a price-to-earnings ratio of 38.59, a PEG ratio of 3.41 and a beta of 1.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.